Last reviewed · How we verify
Selegiline Transdermal System
Selegiline Transdermal System, marketed by Somerset Pharmaceuticals, holds a position in the therapeutic landscape for its indicated use, though specific details on its primary indication and revenue are not provided. A key strength of the product is its unique transdermal delivery mechanism, which may offer a competitive edge over oral formulations. The primary risk to consider is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Selegiline Transdermal System |
|---|---|
| Also known as | EMSAM |
| Sponsor | Somerset Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects (PHASE1)
- Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients (PHASE2)
- Selegiline for Smoking Cessation - 1 (PHASE2)
- Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 (PHASE3)
- Selegiline Patch for Treatment of Nicotine Dependence (PHASE2)
- A Pilot Study Assessing EmSam in Bipolar Depression (PHASE4)
- Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression (PHASE4)
- Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selegiline Transdermal System CI brief — competitive landscape report
- Selegiline Transdermal System updates RSS · CI watch RSS
- Somerset Pharmaceuticals portfolio CI